Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Lung neuroendocrine tumors (NET) are classified as typical (TC) and atypical carcinoids (AT), according to their mitotic count and the presence of necrosis. However, a role for tumor side (right vs left) and location (central vs peripheric) has not been established so far.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: La Salvia A
Authors: La Salvia A, Trevisi E, Brizzi M, Espinosa Olarte P, Enguita A,
Keywords: Lung neuroendocrine tumors, tumor side (left versus right), tumor site (peripheric versus central), prognostic factors, survival,
Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Kaiser K, Webster K, Shaunfield S, Greene G, Yount S,
Keywords: neuroendocrine tumors, priority symptoms, qualitative methods,
Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Chan D, Yao J, Carnaghi C, Buzzoni R, Herbst F,
Keywords: Neuroendocrine tumors, neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, everolimus, RADIANT-3, RADIANT-4, systemic inflammation, prognosis,
Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F,
Keywords: adverse events, everolimus, RADIANT-3, RADIANT-4, landmark analysis, mTOR inhibitors, targeted therapy, neuroendocrine tumors,
Introduction: The majority of all NETs develop in the GI tract and about one third develop in the lungs; approximately 43% and 51% of pts, respectively, are diagnosed with adv disease (regional or distant metastasis). While GI and lung NETs are rare, their incidence has increased markedly over the past four decades. The severe and progressive nature of adv NET suggests significant costs for pts and payers.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Gaasvik L, Aavikko M, Kurki S, Oddershede L,